Peregrine to Report Fourth Quarter and Year-End Fiscal Year 2013 Financial
Results After Market Close on July 11, 2013
TUSTIN, CA -- (Marketwired) -- 07/02/13 -- Peregrine
Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage
biopharmaceutical company developing first-in-class monoclonal
antibodies focused on the treatment and diagnosis of cancer, today
announced that it will report financial results for the fourth
quarter and fiscal year (FY) 2013 on July 11, 2013 after market and
will host a conference call and webcast at 1:30 PM Pacific Daylight
Time (4:30 PM Eastern Daylight Time). Peregrine's senior management
will discuss financial results for the fourth quarter ended April 30,
2013 of FY 2013 and will review recent progress of its clinical
To listen to the live webcast, or access the archived webcast, please
To listen to the conference call, please dial (877) 312-5443 or (253)
237-1126 and request the Peregrine Pharmaceuticals call. A replay of
the call will be available starting approximately two hours after the
conclusion of the call through July 18, 2013 by calling (855)
859-2056, or (404) 537-3406 and using passcode 10642041.
About Peregrine Pharmaceuticals, Inc.
Inc. is a biopharmaceutical company with a portfolio of innovative
monoclonal antibodies in clinical trials focused on the treatment and
diagnosis of cancer. The company is pursuing multiple clinical
programs in cancer with its lead immunotherapy candidate bavituximab
and novel brain cancer agent Cotara(R). Peregrine also has in-house
cGMP manufacturing capabilities through its wholly-owned subsidiary
Avid Bioservices, Inc. (www.avidbio.com), which provides development
and biomanufacturing services for both Peregrine and third-party
customers. Additional information about Peregrine can be found at
Christopher Keenan or Jay Carlson
Peregrine Pharmaceuticals, Inc.
Press spacebar to pause and continue. Press esc to stop.